Sign in

Oscar R Durón

@osduvar.bsky.social
620 followers 514 following 29 posts

Nephrologist. Enthusiast about all things Nephrology. NPATH fellow 2021-2023. NephEdC Internship 2024.

PostsRepliesMedia
Reposted by Oscar R Durón
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 21/10/2025
The latest empadata dump: @nephroseeker.medsky.social writes up a #NephJC short on the meta analysis www.nephjc.com/news/2025/10...
nephjc.com
Empagliflozin, the kidney, and what we still don’t understand — NephJC
NephJC short on an empagliflozin meta-analysis
12415
Reposted by Oscar R Durón
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 25/04/2025
A one year delay in diagnosis of #hypertension! Clear illustration of the importance of measuring BP in both arms www.ahajournals.org/doi/10.1161/... in @ahajournals.bsky.social Hypertension
Table. Timeline of Clinic Visits and Blood Pressure MeasurementsFigure. Computed tomography angiography (CTA) of subclavian artery stenosis. Axial CTA image of this patient with subclavian artery stenosis. A, Patent subclavian artery (indicated by the arrow) distal to the site of the occlusion. B, A more inferior axial image with an absence of contrast in the subclavian artery at the level of the subtotal occlusion while (C) demonstrates the most inferior and proximal to the aortic arch and re-demonstrates a patent proximal portion of the subclavian artery. This is consistent with a subtotal occlusion of the subclavian artery with distal reconstitution likely via the left vertebral artery
13210
Reposted by Oscar R Durón
kireports.bsky.social @kireports.bsky.social · 26/03/2025
Our topic: Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest. #MedSky #NephSky Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
kireports.org
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays the progression of chronic kidney disease (CKD), its effect on patients with autosomal dominant polycystic kidney dis...
173
Reposted by Oscar R Durón
Nephrology Journal Club @nephjc.bsky.social · 25/03/2025
Check out the VA from @nephroseeker.medsky.social 👀 Join us tonite at 9pm EST to discuss @kdigo.org ADPKD 2025 guidelines 📚 #NephSky#MedSky #NephJC www.nephjc.com/news/2025/kdigo-adpkd-va
nephjc.com
The first KDIGO ADPKD guideline — NephJC
The KDIGO ADPKD guideline is a result of a decade of global collaboration between physicians, researchers, advocates, and patients. 240 pages summarized in only 2 pictures, made by Cristina Popa .
0136
Reposted by Oscar R Durón
Nephrology Journal Club @nephjc.bsky.social · 12/03/2025
Not lastly, #NephSky #MedSky ✨This year we try something new: #nephjc internship If curious, wanna apply, need to be part of our world-wide community, apply 👇
0147
Reposted by Oscar R Durón
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 19/03/2025
Drugs or devices? For #NephMadness, I make my choice ajkdblog.org/2025/03/19/n... Let’s see if the wise #BlueRibbonFail panel likes similar sensible solutions!
ajkdblog.org
#NephMadness 2025: Renal Denervation in Hypertension: Fad or Fixture?
Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness 2025   Swapnil Hiremath Swapnil Hiremath is a Professor at the University of Ottawa and an Associate Scientist at the Otta…
0138
Reposted by Oscar R Durón
American Journal of Kidney Diseases @ajkd.bsky.social · 15/03/2025
Need weekend plans? Catch up on all the #NephMadness 2025 regions: -Resistant Hypertension -Obesity -Green House -Minimal Change Disease -Disaster Nephrology -Genetics -Hemodialysis -CAR-T for Kidney Disease Happy reading! bit.ly/4iMNijV
062
Oscar R Durón @osduvar.bsky.social · 19/02/2025
A question to all Nephrologists, how do you approach the difference in proteinuria between samples of spot urine and 24 hr urine? In this example: - Spot Urine Alb/Cr ratio: 938 mg/g - 24 hrs: 2,177 mg/24 hrs My calculations for Alb/Cr ratio in 24 hr is 985 mg/g #AskRenal
341
Reposted by Oscar R Durón
Nephrology Journal Club @nephjc.bsky.social · 17/12/2024
🎨The visual abstract made by @drnikhil.bsky.social #NephSKy #MedSKy, tonight #NephJC goes with an oldie but still goldie topic: RASi in advanced CKD ⏰ Same hour, 9 pm EST www.nephjc.com/news/2024/12...
02011
Reposted by Oscar R Durón
Nephrology Journal Club @nephjc.bsky.social · 17/12/2024
Is it ever too late to start RAS inhibitors in CKD? www.nephjc.com/news/aceing-... from @osduvar.bsky.social Join us this week to discuss on #NephJC
nephjc.com
ACEing the management of advanced CKD — NephJC
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
2299
Oscar R Durón @osduvar.bsky.social · 17/12/2024
Afraid of RASi on advanced CKD? Should we initiate ACEi and ARBs in stage 4 CKD? Is it safe? Is it worth the risk? Find the answers in this week’s #NephJC blogpost about the most recent meta-analysis on the subject. Spoiler: Keep Calm and Aceit! www.nephjc.com/news/aceing-...
nephjc.com
ACEing the management of advanced CKD — NephJC
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
040
Oscar R Durón @osduvar.bsky.social · 13/11/2024
“Inner work is not all ecstatic surrender. Don’t listen too often[…] to the comforting part of the self that gives you what you want. Pray instead for a tough instructor.” - The Essential Rumi
040